ScinoPharm, Sundia MediTech Partner for Pharma Outsourcing in China
ScinoPharm Changshu Pharmaceuticals and Sundia MediTech form an alliance for contract research and manufacturing services in mainland China.
ScinoPharm Changshu Pharmaceuticals and Sundia MediTech have formed a strategic alliance to for contract research and manufacturing Services (CRAMS) in mainland China.
This cooperation combines Sundia’s capabilities in new drug R&D with ScinoPharm’s process R&D and commercial production expertise, especially in the field of highly potent oncological APIs. Under the alliance, both parties will be able to further support customer needs with one-stop solutions for integrated services such as drug development, research, clinical trials, and commercial manufacturing.
Sondia MediTech is a Shanhai-based CRO with a research team of 600 employees. ScinoPharm Changsho, located in the Jiangsu Province in China is a subsidiary of ScinoPharm Taiwan.
Source: ScinoPharm
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
